Boston Scientific launches Promus Premier drug-eluting stent in Japan

Boston Scientific's Promus Premier coronary stent--Courtesy of Boston Scientific

Boston Scientific ($BSX) rolled out its Promus Premier next-generation drug-eluting coronary stent system in Japan. The everolimus-releasing platinum-chromium stent is part of the company's sales and marketing strategy as it looks for a blockbuster product to kick-start its revenue growth. "Japan is an important interventional cardiology market, and we believe the launch and success of this stent system in Japan will enhance Boston Scientific's overall growth strategy in the DES [drug eluting stent] market," said interventional cardiology president Kevin Ballinger in a statement. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.